Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 282 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 282 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $12,661.80. Following the completion of the transaction, the senior vice president now directly owns 133,433 shares of the company’s stock, valued at approximately $5,991,141.70. The trade was a 0.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Paula Green also recently made the following trade(s):

• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10.

Twist Bioscience Price Performance

TWST stock opened at $49.22 on Friday. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The firm has a market capitalization of $2.92 billion, a PE ratio of -13.67 and a beta of 1.82. The company’s 50 day simple moving average is $45.51 and its 200-day simple moving average is $46.72.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TWST shares. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Robert W. Baird boosted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $51.90.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience in the third quarter valued at $34,000. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience in the 2nd quarter valued at about $61,000. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the 3rd quarter worth about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.